Phgdh-flox Mouse
Common Name
Phgdh-flox
제품 ID
S-CKO-07879
Backgroud
C57BL/6JCya
품종 계통계통 ID
CKOCMP-236539-Phgdh-B6J-VB
상태
이 마우스 계통을 논문에서 사용할 경우, “Phgdh-flox Mouse (카탈로그 번호 S-CKO-07879)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Phgdh-flox
품종 계통계통 ID
CKOCMP-236539-Phgdh-B6J-VB
유전자명
제품 ID
S-CKO-07879
유전자 별칭
A10, PGD, PGAD, PGDH, SERA, 3PGDH, 3-PGDH, 4930479N23
배경
C57BL/6JCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 3
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000065793
NCBI 전사체 ID
NM_016966
타겟 영역
Exon 2~3
유효 영역 크기
~2.8 kb
유전자 연구 개요
Phgdh, also known as PhosphoGlycerol Dehydrogenase, is the first rate-limiting enzyme in the serine biosynthesis pathway, catalyzing the conversion of 3-phosphoglycerate to 3-phosphohydroxypyruvate. Serine synthesis is crucial for macromolecule synthesis, neutralizing oxidative stress, and regulating methylation reactions. This pathway is associated with various biological processes such as cell proliferation, metastasis, and immune-related functions [1,3,4,6].
In bladder cancer, knockdown of Phgdh promoted ferroptosis and decreased cancer cell proliferation while downregulating SLC7A11 expression. Phgdh interacts with PCBP2, inhibiting its ubiquitination degradation, and PCBP2 in turn stabilizes SLC7A11 mRNA [1]. In breast cancer, loss of Phgdh potentiated metastatic dissemination, with low Phgdh expression in primary tumors associated with decreased metastasis-free survival. Mechanistically, loss of the interaction between Phgdh and phosphofructokinase activated the hexosamine-sialic acid pathway, leading to aberrant protein glycosylation and increased cell migration [2]. In hepatocellular carcinoma, PRMT1-mediated methylation of Phgdh at arginine 236 enhanced its catalytic activity, promoting serine synthesis and tumor growth. Blocking this methylation inhibited serine synthesis and restrained tumor growth [4]. In glioblastoma, genetic ablation of Phgdh in endothelial cells pruned over-sprouting vasculature, abrogated intratumoral hypoxia, and improved T-cell infiltration. In HCC, inactivation of Phgdh reduced the production of key metabolites, elevated ROS levels, and induced apoptosis upon Sorafenib treatment. The Phgdh inhibitor NCT-503 worked synergistically with Sorafenib to abolish HCC growth. In pre-clinical models of brain metastasis, genetic suppression and pharmacologic inhibition of Phgdh attenuated brain metastasis but not extracranial tumor growth [5,7,8].
In conclusion, Phgdh plays a vital role in serine synthesis, which impacts multiple biological processes and disease conditions. Gene knockout and other loss-of-function models have revealed its significance in cancer metastasis, tumor growth, and response to therapies in various cancers, highlighting its potential as a therapeutic target [1-2,4-5,9-10].
References:
1. Shen, Liliang, Zhang, Junfeng, Zheng, Zongtai, Zhang, Wentao, Yao, Xudong. 2022. PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer. In International journal of biological sciences, 18, 5459-5474. doi:10.7150/ijbs.74546. https://pubmed.ncbi.nlm.nih.gov/36147463/
2. Rossi, Matteo, Altea-Manzano, Patricia, Demicco, Margherita, Rheenen, Jacco van, Fendt, Sarah-Maria. 2022. PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. In Nature, 605, 747-753. doi:10.1038/s41586-022-04758-2. https://pubmed.ncbi.nlm.nih.gov/35585241/
3. Cai, Zhengnan, Li, Wan, Hager, Sonja, Heffeter, Petra, Weckwerth, Wolfram. 2024. Targeting PHGDH reverses the immunosuppressive phenotype of tumor-associated macrophages through α-ketoglutarate and mTORC1 signaling. In Cellular & molecular immunology, 21, 448-465. doi:10.1038/s41423-024-01134-0. https://pubmed.ncbi.nlm.nih.gov/38409249/
4. Wang, Kui, Luo, Li, Fu, Shuyue, Wei, Xiawei, Huang, Canhua. 2023. PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma. In Nature communications, 14, 1011. doi:10.1038/s41467-023-36708-5. https://pubmed.ncbi.nlm.nih.gov/36823188/
5. Zhang, Duo, Li, Albert M, Hu, Guanghui, Gong, Yanqing, Fan, Yi. 2023. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. In Cell metabolism, 35, 517-534.e8. doi:10.1016/j.cmet.2023.01.010. https://pubmed.ncbi.nlm.nih.gov/36804058/
6. Lee, Chae Min, Hwang, Yeseong, Kim, Minki, Kim, Hyeonhui, Fang, Sungsoon. 2024. PHGDH: a novel therapeutic target in cancer. In Experimental & molecular medicine, 56, 1513-1522. doi:10.1038/s12276-024-01268-1. https://pubmed.ncbi.nlm.nih.gov/38945960/
7. Wei, Lai, Lee, Derek, Law, Cheuk-Ting, Wong, Carmen Chak-Lui, Wong, Chun-Ming. 2019. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. In Nature communications, 10, 4681. doi:10.1038/s41467-019-12606-7. https://pubmed.ncbi.nlm.nih.gov/31615983/
8. Ngo, Bryan, Kim, Eugenie, Osorio-Vasquez, Victoria, Cantley, Lewis C, Pacold, Michael E. 2020. Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. In Cancer discovery, 10, 1352-1373. doi:10.1158/2159-8290.CD-19-1228. https://pubmed.ncbi.nlm.nih.gov/32571778/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
